Clovis Oncology (CLVS) Misses Q4 EPS by 25c

Clovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($1.02), $0.25 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $43.3 million versus the consensus estimate of $43.22 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
• Vireo Growth completes acquisition of C21 Investments